Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abivax Sa ADR (ABVX)

Abivax Sa ADR (ABVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,611,001
  • Shares Outstanding, K 77,829
  • Annual Sales, $ 0 K
  • Annual Income, $ -190,710 K
  • EBIT $ -103 M
  • EBITDA $ -101 M
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 100.53% (+0.09%)
  • Historical Volatility 57.43%
  • IV Percentile 82%
  • IV Rank 57.20%
  • IV High 141.82% on 11/20/25
  • IV Low 45.36% on 10/22/25
  • Expected Move (DTE 14) 13.30 (12.13%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,560
  • Volume Avg (30-Day) 2,712
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 33,048
  • Open Int (30-Day) 27,941
  • Expected Range 96.38 to 122.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.50 +9.13%
on 11/13/25
130.25 -15.80%
on 11/26/25
+10.07 (+10.10%)
since 11/05/25
3-Month
80.11 +36.91%
on 09/18/25
130.25 -15.80%
on 11/26/25
+21.65 (+24.59%)
since 09/05/25
52-Week
4.77 +2,199.27%
on 04/09/25
130.25 -15.80%
on 11/26/25
+101.35 (+1,216.63%)
since 12/05/24

Most Recent Stories

More News
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst

In a report released on October 6, Thomas Smith from Leerink Partners reiterated a Buy rating on Abivax SA Sponsored ADR. The company’s shares closed yesterday at $87.01.Elevate Your Investing Strategy:...

ABVX : 110.99 (+0.32%)
Kepler Capital Sticks to Their Buy Rating for Abivax SA (0RA9)

Kepler Capital analyst Justine Telliez maintained a Buy rating on Abivax SA on October 6 and set a price target of €70.00. The company’s shares closed yesterday at €73.50.Elevate Your Investing Strategy:...

ABVX : 110.99 (+0.32%)
Why This French Biotech Stock Just Soared 586% in One Day

Shares of Abivax SA (NASDAQ: ABVX) went parabolic on Wednesday, skyrocketing 586% to close at $68.60 after the French biotech firm announced overwhelmingly positive Phase 3 data for its lead drug candidate,...

NDAQ : 90.19 (+0.19%)
PTN : 21.50 (-2.23%)
ABVX : 110.99 (+0.32%)
PTNT : 8.5300 (-15.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax SA is based in PARIS, FRANCE.

See More

Key Turning Points

3rd Resistance Point 118.63
2nd Resistance Point 115.60
1st Resistance Point 113.12
Last Price 110.99
1st Support Level 107.61
2nd Support Level 104.58
3rd Support Level 102.10

See More

52-Week High 130.25
Last Price 110.99
Fibonacci 61.8% 82.32
Fibonacci 50% 67.51
Fibonacci 38.2% 52.70
52-Week Low 4.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar